NBIX (STOCKS)
Neurocrine Biosciences Inc
$126.320000
-2.570000 (-1.99%)
Prev close: $128.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Kyle W. Gano
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $12,676.91M
- Employees
- 1,800
- P/E (TTM)
- 27.60
- P/B (TTM)
- 3.97
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
13
Strong Buy
18
Buy
5
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.48 | $1.92 | -0.4394 | -22.89% |
|
Sep 2025 (Q3)
|
$2.04 | $1.62 | +0.4223 | +26.11% |
|
Jun 2025 (Q2)
|
$1.06 | $0.99 | +0.0693 | +7.00% |
|
Mar 2025 (Q1)
|
$0.08 | $0.56 | -0.4764 | -85.62% |
Financial Statements
| Revenues | $2.86B |
| Benefits Costs and Expenses | $2.16B |
| Cost Of Revenue | $52.10M |
| Costs And Expenses | $2.24B |
| Gross Profit | $2.81B |
| Nonoperating Income/Loss | $86.30M |
| Operating Expenses | $2.19B |
| Selling, General, and Administrative Expenses | $1.16B |
| Other Operating Expenses | $1.03B |
| Operating Income/Loss | $619.10M |
| Income/Loss From Continuing Operations After Tax | $478.60M |
| Income/Loss From Continuing Operations Before Tax | $705.40M |
| Income Tax Expense/Benefit | $226.80M |
| Income Tax Expense/Benefit, Current | $62.60M |
| Income Tax Expense/Benefit, Deferred | $164.20M |
| Net Income/Loss | $478.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $478.60M |
| Net Income/Loss Available To Common Stockholders, Basic | $478.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $4.81 |
| Diluted Earnings Per Share | $4.67 |
| Basic Average Shares | 99,500,000 |
| Diluted Average Shares | 102,500,000 |
| Assets | $4.63B |
| Current Assets | $2.52B |
| Inventory | $69.00M |
| Prepaid Expenses | $170.70M |
| Other Current Assets | $2.28B |
| Noncurrent Assets | $2.11B |
| Fixed Assets | $89.80M |
| Other Non-current Assets | $2.02B |
| Liabilities | $1.38B |
| Current Liabilities | $743.40M |
| Wages | $128.80M |
| Other Current Liabilities | $614.60M |
| Noncurrent Liabilities | $635.00M |
| Equity | $3.25B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.25B |
| Liabilities And Equity | $4.63B |
| Net Cash Flow From Operating Activities | $782.70M |
| Net Cash Flow From Operating Activities, Continuing | $782.70M |
| Net Cash Flow From Investing Activities | -$264.40M |
| Net Cash Flow From Investing Activities, Continuing | -$264.40M |
| Net Cash Flow From Financing Activities | -$38.30M |
| Net Cash Flow From Financing Activities, Continuing | -$38.30M |
| Exchange Gains/Losses | $0.00 |
| Net Cash Flow | $480.00M |
| Net Cash Flow, Continuing | $480.00M |
| Comprehensive Income/Loss | $485.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $485.90M |
| Other Comprehensive Income/Loss | $7.30M |